EP Patent

EP0401705A3 — Use of an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease

Assigned to ER Squibb and Sons LLC · Expires 1993-01-07 · 33y expired

What this patent protects

A use of a pharmaceutical composition is provided for treating peripheral atherosclerotic disease (arte­ riosclerosis obliterans) and/or intermittent claudication containing an HMG CoA reductase inhibitor alone and/or inhibitor of the enzyme squalene synthetase and optionally …

USPTO Abstract

A use of a pharmaceutical composition is provided for treating peripheral atherosclerotic disease (arte­ riosclerosis obliterans) and/or intermittent claudication containing an HMG CoA reductase inhibitor alone and/or inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil.

Drugs covered by this patent

Patent Metadata

Patent number
EP0401705A3
Jurisdiction
EP
Classification
—
Expires
1993-01-07
Drug substance claim
No
Drug product claim
No
Assignee
ER Squibb and Sons LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.